The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Open accessAbstract
B-cell maturation antigen (BCMA)–targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety and efficacy of cilta-cel, an anti-BCMA chimeric antigen receptor T therapy, in various myeloma patient populations. Patients in cohort C progressed despite treatment with a proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and noncellular anti-BCMA immunotherapy. A single cilta-cel infusion was given after lymphodepletion. The primary end point was minimal residual disease (MRD) negativity at 10−5. Overall, 20 patients were treated (13 ADC exposed; 7 BsAb exposed; 1 in the ADC group also had prior BsAb exposure). Sixteen (80%) were refractory to prior anti-BCMA therapy. At a median follow-up of 11.3 months (range, 0.6-16.0), 7 of 20 (35%) patients were MRD negative (7 of 10 [70.0%] in the MRD-evaluable subset). Overall response rate (95% confidence interval [CI]) was 60.0% (36.1-80.9). Median duration of response and progression-free survival (95% CI) were 11.5 (7.9—not estimable) and 9.1 (1.5—not estimable) months, respectively. The most common adverse events were hematologic. Cytokine release syndrome occurred in 12 (60%) patients (all grade 1-2); 4 had immune effector cell-associated neurotoxicity syndrome (2 had grade 3-4); none had parkinsonism. Seven (35%) patients died (3 of progressive disease, 4 of adverse events [1 treatment related, 3 unrelated]). Cilta-cel induced favorable responses in patients with relapsed/refractory MM and prior exposure to anti-BCMA treatment who had exhausted other therapies. This trial was registered at www.clinicaltrials.gov as NCT04133636.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationCohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00629-1 · Cited by 308
Self-citationRisk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
Mohan, M., Nagavally, S., Dhakal, B., Radhakrishnan, S. V., Chhabra, S., D’Souza, A., & Hari, P. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006178 · Cited by 66
Sebag, M., Raje, N. S., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Dube, H., Damore, M. A., et al. (2021) · Blood · doi:10.1182/blood-2021-150519 · Cited by 54
Clarification of the definition of complete response in multiple myeloma
Durie, B. G. M., Miguel, J. F. S., Blade, J., Rajkumar, S. V., & on behalf of the International Myeloma Working Group (2015) · Leukemia · doi:10.1038/leu.2015.290 · Cited by 42
Self-citation
Cited by
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Nooka, A. K., Cohen, A. D., Lee, H. C., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E. N., et al. (2023) · Cancer · doi:10.1002/cncr.34987 · Cited by 73
Self-citationClinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab
Chari, A., Krishnan, A., Rasche, L., Ye, J. C., Garfall, A., Popat, R., Lipe, B., Qin, X., Campagna, M., Masterson, T., et al. (2024) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2024.05.003 · Cited by 53
Metadata
- Authors
- Cohen, A. D., Mateos, M.-V., Cohen, Y. C., Rodriguez-Otero, P., Paiva, B., van de Donk, N. W. C. J., Martin, T., Suvannasankha, A., De Braganca, K. C., Corsale, C., Schecter, J. M., Varsos, H., Deraedt, W., Wang, L., Vogel, M., Roccia, T., Xu, X., Mistry, P., Zudaire, E., Akram, M., Nesheiwat, T., Pacaud, L., Avivi, I., & San-Miguel, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2023-01-19
- Volume
- 141
- Issue
- 3
- Pages
- 219-230
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4295424675
- Cited by
- 213
- References
- 9
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. https://app.cochat.ai/papers/10.1182/blood.2022015526
- The paper
- Cohen, A. D., Mateos, M.-V., Cohen, Y. C., Rodriguez-Otero, P., Paiva, B., van de Donk, N. W. C. J., Martin, T., Suvannasankha, A., De Braganca, K. C., Corsale, C., Schecter, J. M., Varsos, H., Deraedt, W., Wang, L., Vogel, M., Roccia, T., Xu, X., Mistry, P., Zudaire, E., . . . San-Miguel, J. (2023). Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. https://doi.org/10.1182/blood.2022015526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.